Table 2.

Characteristics, management and outcomes of rheumatic irAEs

Patient	Rheumatic irAE	Time to onset (weeks)	bDMARD/ tsDMARD	Previous treatment for irAE	bDMARD/ tsDMARD duration (weeks)	irAE outcome	Cancer outcome	GC tapering (mg/day)
1	RA-like	131	Etanercept	GC, MTX	86 (ongoing)	Resolution	Remission	0
2	RA-like	22	Infliximab	GC, MTX	8	Resolution	Progression	0
3	RA-like	14	Tocilizumab	GC, MTX	8	Partial improvement	Progression	20
4	RA-like	16	Tocilizumab	GC	34	Partial improvement	Progression*	10
5	PMR-like	3	Tocilizumab	GC	53 (ongoing)	Partial improvement	Stable	2
6	RA-like	24	Tocilizumab	GC, MTX	69 (ongoing)	Resolution	Remission	0
7	RA-like	2	Tocilizumab	GC, MTX	8	Resolution	Progression*	10
8	PMR-like	48	Tocilizumab	GC, MTX	48 (ongoing)	Resolution	Remission	0
9	PsA-like	8	Tocilizumab	NSAIDs, GC, MTX	43 (ongoing)	Partial improvement	Progression	2.5
10	RA-like	33	1/Tocilizumab 2/Baricitinib	GC, MTX	1/6 2/78 (ongoing)	1/No improvement 2/Resolution	Progression	0
11	PsA-like	34	Ustekinumab	GC	60 (ongoing)	Partial improvement	Stable	5
12	RA-like	20	Adalimumab	GC, MTX	8 (ongoing)	Resolution	Remission	0
13	RA-like	26	Adalimumab	GC	34	Partial improvement	Progression	5
14	RA-like	16	Tocilizumab	GC, MTX	8	No improvement	Remission	5
15	RA-like	64	Tocilizumab	GC, MTX	17	Partial improvement	Progression	5
16	RA-like	156	Tocilizumab	GC	8 (ongoing)	Partial improvement	Stable	5
17	RA-like	22	Sarilumab	NSAIDs, GC, MTX	12 (ongoing)	Partial improvement	Partial response	7.5
18	RA flare	0	Tocilizumab	GC	22	Partial improvement	Progression*	15
19	RA-like	69	Anakinra	Colchicine	1	No improvement	Stable	0
20	RA flare	1	Etanercept	GC	8	No improvement	Progression*	80

*Death.

bDMARD, biologic disease-modifying antirheumatic drug; GC, glucocorticoids; irAE, immune-related adverse event; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PMR, polymyalgia rheumatica; PsA, psoriatic arthritis; RA, rheumatoid arthritis; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.